NanoViricides
Update in progressNNVC (NYSE American)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
NanoViricides, Inc. is a clinical-stage nano-biopharmaceutical company focused on antiviral drugs. Its NV-387 program targets RSV, influenza, and COVID-19, with formulations such as NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, plus an injectable and a nebulized lung-delivery form for respiratory infections. The pipeline also includes NV-HHV-1 for shingles and HSV-1/HSV-2, and HIVCide candidates for Dengue and Ebola. Headquartered in Shelton, CT.
Company score
- Sentiment
- 0.23
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.21
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE American (ASE)
- LocationUnited States
- CEODr. Anil R. Diwan Ph.D.
- Founded2005
- Employees7
- Websitewww.nanoviricides.com
Identifiers
- ISINUS6300873022
- FIGIBBG000C0WN63
- LEI5493003CK9Y2H0OORR73
- CUSIP630087104
- CIK0001379006